Session » Abstracts: Antiphospholipid Syndrome (0855–0860)
- 10:00AM-10:15AM
-
Abstract Number: 0855
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
- 10:15AM-10:30AM
-
Abstract Number: 0856
Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
- 10:30AM-10:45AM
-
Abstract Number: 0857
CD14-dependent MAP kinase signaling is required for pathogenic neutrophil extracellular trap formation in APS
- 10:45AM-11:00AM
-
Abstract Number: 0858
IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
- 11:00AM-11:15AM
-
Abstract Number: 0859
Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps